Baker Bros. Advisors LP Incyte Corp Transaction History

Baker Bros. Advisors LP

$9.02 Billion
Q4 2024

A detailed history of Baker Bros. Advisors LP transactions in Incyte Corp stock. As of the latest transaction made, Baker Bros. Advisors LP holds 30,739,466 shares of INCY stock, worth $2.22 Billion. This represents 23.54% of its overall portfolio holdings.

Number of Shares

30,739,466

Previous 30,739,020 -0.0%

Holding current value

$2.22 Billion

Previous $2.03 Billion 4.49%

% of portfolio

23.54%

Previous 21.76%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$65.08 - $83.38 $29,025 - $37,187	446 Added 0.0%	30,739,466 $2.12 Billion
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $28,435 - $34,030	496 Added 0.0%	30,739,020 $2.03 Billion
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $278 Million - $347 Million	-5,441,141 Reduced 15.04%	30,738,524 $1.86 Billion
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $30,706 - $36,158	543 Added 0.0%	36,179,665 $2.06 Billion
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $29,000 - $35,689	556 Added 0.0%	36,179,122 $2.27 Billion
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $29,462 - $33,624	510 Added 0.0%	36,178,566 $2.09 Billion
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $161,883 - $200,554	2,656 Added 0.01%	36,178,056 $2.25 Billion
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $1.43 Million - $1.76 Million	20,429 Added 0.06%	36,175,400 $2.61 Billion
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $26,670 - $33,391	397 Added 0.0%	36,154,971 $2.9 Billion
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $30,244 - $37,867	457 Added 0.0%	36,154,574 $2.41 Billion
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $28,655 - $36,016	433 Added 0.0%	36,154,117 $2.75 Billion
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $167 Million - $202 Million	2,535,621 Added 7.54%	36,153,684 $2.87 Billion
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $101 Million - $118 Million	1,595,938 Added 4.98%	33,618,063 $2.47 Billion
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $26,987 - $33,019	393 Added 0.0%	32,022,125 $2.2 Billion
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.62 Million - $1.78 Million	20,345 Added 0.06%	32,021,732 $2.69 Billion
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $125,128 - $165,423	1,646 Added 0.01%	32,001,387 $2.6 Billion
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $27,693 - $33,511	343 Added 0.0%	31,999,741 $2.78 Billion
Q3 2020 Nov 16, 2020	BUY	$85.07 - $109.69 $26,967 - $34,771	317 Added 0.0%	31,999,398 $2.87 Billion
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $1.51 Million - $2.21 Million	20,296 Added 0.06%	31,999,081 $3.33 Billion
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $120,800 - $164,374	1,912 Added 0.01%	31,978,785 $2.34 Billion
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $23,080 - $30,247	316 Added 0.0%	31,976,873 $2.79 Billion
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $26,506 - $31,493	364 Added 0.0%	31,976,557 $2.37 Billion
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $169 Million - $204 Million	-2,295,634 Reduced 6.7%	31,976,193 $2.72 Billion
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $1.29 Million - $1.78 Million	20,220 Added 0.06%	34,271,827 $2.95 Billion
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $17,433 - $20,842	298 Added 0.0%	34,251,607 $2.18 Billion
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $16,981 - $20,413	275 Added 0.0%	34,251,309 $2.37 Billion
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $1.23 Million - $1.7 Million	20,283 Added 0.06%	34,251,034 $2.29 Billion
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $18,937 - $23,023	228 Added 0.0%	34,230,751 $2.85 Billion
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $18,712 - $23,320	200 Added 0.0%	34,230,523 $3.24 Billion
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $3.74 Billion - $4.73 Billion	34,230,323	34,230,323 $4 Billion

Others Institutions Holding INCY

# of Institutions

706

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account

Baker Bros. Advisors LP Incyte Corp Transaction History